Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: Int J Cardiol. 2014 Dec 23;182:115–120. doi: 10.1016/j.ijcard.2014.12.042

Table 1.

Characteristics of the Study Sample at the 12th Annual Visit

Study Variables Total
N=1103
Age, years, mean(SD) 59.6 (2.7)
Race, n(%)*
White 592 (53.7)
Black 336 (30.5)
Chinese 175 (15.9)
Menopausal Status, n(%)
Not postmenopausal 32 (2.9)
Postmenopausal 1071 (97.1)
Body mass index, Kg/m2, mean(SD) 29.5 (7.3)
Systolic blood pressure, mmHg, mean(SD) 120.6 (16.7)
LDL-C, mg/dL, mean(SD) 120.4 (31.6)
HDL-C, mg/dL, mean(SD) 62.7 (16.3)
Triglycerides, mg/dL, median (IQR) 96.0 (73.0, 134.0)
HOMA insulin resistance index, median (IQR) 2.0 (1.2, 3.6)
Smoking status, n(%)
Never 689 (62.5)
Ever 321 (29.1)
Current 93 (8.4)
Ever use of cardiovascular medications, n(%) 584 (53.0)
Ever use of HT, n(%) 390 (35.4)
Diabetic, n(%) 105 (9.5)
Physical activity score, mean(SD) 7.7 (1.8)
cIMT, mm, mean(SD) 0.79 (0.1)
cAD, mm, mean (SD) 7.2 (0.6)
Level of plaque burden, n(%)
None 609 (55.2)
Minimal 215 (19.5)
High 279 (25.3)
Average time needed for sit-to-stand, s, median (IQR) 1.1 (0.8, 1.5)
Average walking speed, m/s, mean (SD) 1.4 (0.3)

LDL-C: low density lipoprotein cholesterol, HDL-C: high density lipoprotein cholesterol, cIMT: carotid intima-media thickness, cAD: carotid adventitial diameter

*

Los Angeles site did not participate in carotid ultrasound assessment and therefore data were not available for the Japanese participants of the SWAN study

Ever use of cardiovascular medications including antihypertensive, lipid-lowering and heart medications